EGRXOTCdelisted

EAGLE PHARMACEUTICALS, INC.

Healthcare·Oncology·Commercial·Woodcliff Lake, NJ, United States
OncologyNeurologyInfectious DiseaseMetabolic

EAGLE PHARMACEUTICALS, INC. (EGRX): 4 pipeline candidates · ~1593 mo cash runway · 2 clinical trials. Updated within the last hour.

8.9/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

1593.4 months

Financial Health8.2

D/E 0.61

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for EAGLE PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$3.3M

Cash

$15.4M

Quarterly Burn

$126K

Runway

1593.4 mo

Revenue

$64.6M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Apr 2159
Today~1753 mo out
Catalyst within runway

Pipeline (4 candidates)

DrugPhase
belrapzoApproved
cal02Phase 2
pemfexyApproved
ryanodexApproved
2 clinical trials·CEO: Mr. Michael Graves

Frequently asked questions

How many drug candidates are in EAGLE PHARMACEUTICALS, INC.'s pipeline?

EAGLE PHARMACEUTICALS, INC. (EGRX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is EAGLE PHARMACEUTICALS, INC.'s lead drug candidate?

EAGLE PHARMACEUTICALS, INC.'s most advanced tracked candidate is belrapzo (Approved) for 1 INDICATIONS AND USAGE BELRAPZO is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BELRAPZO is indicated for the treatment of patients with chronic l.

What is EAGLE PHARMACEUTICALS, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, EAGLE PHARMACEUTICALS, INC. has approximately 1593.4 months of cash runway.

What is EAGLE PHARMACEUTICALS, INC.'s market capitalization?

EAGLE PHARMACEUTICALS, INC.'s market capitalization is approximately $3.3M.

Who is the CEO of EAGLE PHARMACEUTICALS, INC.?

Mr. Michael Graves is the chief executive officer of EAGLE PHARMACEUTICALS, INC. (EGRX).

Get the full picture on EAGLE PHARMACEUTICALS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar